Cefiderocol

Cefiderocol
Clinical data
Trade names	Fetroja, Fetcroja
Other names	RSC-649266
AHFS/Drugs.com	Monograph
MedlinePlus	a620008
License data	EU EMA: by INN; US DailyMed: Cefiderocol_sulfate_tosylate;
Routes of; administration	Intravenous infusion
Drug class	Siderophore cephalosporins
ATC code	J01DI04 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	56–58%
Elimination half-life	2.8 hours
Excretion	mainly kidney (60–70% unchanged)
Identifiers
	IUPAC name (6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-3-[[1-[2-[(2-chloro-3,4-dihydroxybenzoyl)amino]ethyl]pyrrolidin-1-ium-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;
CAS Number	1225208-94-5;
PubChem CID	77843966;
DrugBank	DB14879;
ChemSpider	52084902;
UNII	SZ34OMG6E8;
KEGG	D11013; D11302;
ChEBI	CHEBI:140376;
ChEMBL	ChEMBL3989974;
Chemical and physical data
Formula	C30H34ClN7O10S2
Molar mass	752.21 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)[O-];
	InChI InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1; Key:DBPPRLRVDVJOCL-FQRUVTKNSA-N;

Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.

Common side effects include diarrhea, infusion site reactions, constipation and rash.

Cefiderocol is in the cephalosporin family of medications. It was approved for medical use in the United States in November 2019, and in the European Union in April 2020. In September 2020, cefiderocol (Fetroja) received FDA approval as supplemental New Drug Application (sNDA) for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) when caused by Gram-negative bacteria resistant to other antibiotics. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.